Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

As the property security landscape evolves, Cloudastructure is strategically expanding its salesforce to address growing ...

Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

Europe has more oncology startups than the U.S., but many more U.S. companies scale up to the later growth stage. Given the ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...